ArticleGynecologic oncology2025

Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary.

C Washington et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.